Cargando…

Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?

INTRODUCTION: High rates of hepatotoxicity have been observed among HIV-positive pregnant women using antiretroviral therapy (ART). However, the extent to which pregnancy affects the risk of ART-induced hepatotoxicity is unclear since studies in this area have generated conflicting results. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huntington, Susie, Thorne, Claire, Anderson, Jane, Newell, Marie-Louise, Taylor, Graham, Pillay, Deenan, Hill, Teresa, Tookey, Pat, Sabin, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Oral Presentation – Abstract O133
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224861/ https://www.ncbi.nlm.nih.gov/pubmed/25393995 http://dx.doi.org/10.7448/IAS.17.4.19486

Ejemplares similares

Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
por: Huntington, Susie, et al.
Publicado: (2014)

Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
por: Huntington, Susie E, et al.
Publicado: (2012)

Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study
por: May, M, et al.
Publicado: (2012)

Impact of the COVID-19 pandemic on overall percutaneous coronary interventions from the France-PCI registry: Comparative analysis of the years 2019 and 2020
por: Mesrar, H., et al.
Publicado: (2023)

Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up
por: Violari, A, et al.
Publicado: (2012)

Review of life expectancy in people with HIV in settings with optimal ART access: what we know and what we don't
por: Sabin, C
Publicado: (2012)

Evaluation of self-perception of awake bruxism in dentistry students – clinical case series
por: Ramos, R., et al.
Publicado: (2021)

Une localisation exceptionnelle de démodécidose en post infection COVID-19
por: Lahouel, I., et al.
Publicado: (2021)

A CASE SERIES: CHRONIC INDUCIBLE URTICARIA FOLLOWING COVID-19 INFECTION AND MRNA VACCINE
por: Hellu, T., et al.
Publicado: (2022)

THE IMPORTANCE OF B CELLS IN OVERCOMING COVID-19 INFECTION IN COMMON VARIABLE IMMUNODEFICIENCY PATIENTS.
por: Brozyna, J., et al.
Publicado: (2022)

Étude du syndrome post-COVID-19 chez les travailleurs du secteur tertiaire
por: Hamadouche, Mohamed, et al.
Publicado: (2023)

Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study
por: O'Connor, Jemma, et al.
Publicado: (2014)

Strategies for Monitoring Outcomes in HIV-Exposed Uninfected Children in the United Kingdom
por: Thorne, Claire, et al.
Publicado: (2016)

Classic Text No. 133: ‘Maxwell Jones and the Therapeutic Community’, by David Millard (1996)
por: Fees, Craig, et al.
Publicado: (2022)

Adverse events: ART and the kidney: alterations in renal function and renal toxicity
por: Post, Frank
Publicado: (2014)

Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018
por: Hill, Andrew, et al.
Publicado: (2014)

573 The Impact of Burn Injuries on Indigenous Populations
por: Gabriel, Vincent, et al.
Publicado: (2023)

Pregnancy outcomes in women growing up with perinatally acquired HIV in the United Kingdom and Ireland
por: Byrne, Laura, et al.
Publicado: (2014)

CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression
por: Costagliola, Dominique, et al.
Publicado: (2014)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Clinical significance of conduction velocity orientation vectors on cardiac mapping surfaces
por: Rodriguez Padilla, J, et al.
Publicado: (2023)

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
por: Gatell, Josep M, et al.
Publicado: (2014)

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
por: Smith, Colette, et al.
Publicado: (2014)

Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study
por: Hatleberg, Camilla Ingrid, et al.
Publicado: (2014)

Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland
por: Tookey, Pat A., et al.
Publicado: (2016)

Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points
por: Raymond, Alice, et al.
Publicado: (2014)

When to start: as soon as possible
por: Saag, M
Publicado: (2012)

When to start: not so fast
por: Lundgren, J
Publicado: (2012)

Late presenters: what can we do?
por: Mussini, C
Publicado: (2012)

TB and HIV: how can we reduce mortality?
por: Lawn, S
Publicado: (2012)

HIV drug resistance surveillance in low- and middle-income countries: 2004 to 2010
por: Bertagnolio, S, et al.
Publicado: (2012)

Treatment optimization in low- and middle-income countries
por: Cooper, D
Publicado: (2012)

HIV, co-morbidity and ageing
por: Reiss, P
Publicado: (2012)

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3
por: Nichols, G, et al.
Publicado: (2012)

Eliminating paediatric infections and keeping mothers alive
por: Gray, G
Publicado: (2012)

HIV in women
por: Mulcahy, F
Publicado: (2012)

Clinical pharmacokinetics of antiretroviral drugs in Ugandan patients
por: Lamorde, M
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_47bmhevtegbmk5oi803i39ki22